Drug Trial Radar · NCT07805356
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Jan 2028
Study completion Jan 2033
Sponsor
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).
Conditions
- Hypoparathyroidism
- Chronic Hypoparathyroidism
Interventions
EncaleretDrug
Oral tablets
PlaceboDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Responders who Achieve Both Albumin-Corrected Blood Calcium (cCa) and 24-hour Urine Calcium (UCa) Within the Protocol-defined Target RangeTime frame: Week 24
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
Indianapolis, Indiana · Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
Boston, Massachusetts · Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
Reno, Nevada · Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
Greenville, North Carolina · Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
Morehead City, North Carolina · Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
Columbus, Ohio · Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
Philadelphia, Pennsylvania · Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
El Paso, Texas · Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
Oakville, Ontario, Canada · Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site
Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.